When AstraZeneca’s Alexion picked up rare disease specialist Syntimmune in 2018 for $ | A Delaware judge agreed that ...

Samsung Bioepis’s biosimilar EPYSQLI® (eculizumab-aagh) was approved by the FDA on July 22, 2024. Alexion had sought a preliminary injunction to prevent the launch of EPYSQLI®, but the Delaware court ...

Gefurulimab is under clinical development by Alexion Pharmaceuticals and currently in Phase III for Myasthenia Gravis.

Alexion Pharmaceuticals Inc. could later be ordered to pay more in damages for another claim in which Zurn ruled against it, ...

We provide a rundown of Managing IP’s news and analysis from the week, and review what’s been happening elsewhere in IP ...

Baker Brothers' 13F portfolio value decreased from $7.97B to $7.83B this quarter. Click here to read more about its fund ...

Claude Nicaise, M.D. appointed Chairman of the BoardAUSTIN, Texas, Sept. 09, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: SAVA), a ...

LEXINGTON, Mass., Sept. 16, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: VYGR), a biotechnology company dedicated to advancing ...

Fintel reports that on September 19, 2024, JP Morgan downgraded their outlook for Halozyme Therapeutics (NasdaqGS:HALO) from ...

Alexion has said it can ramp up production if the drug works in trials but what it has not mentioned is its cost: Ultomiris is hugely expensive when used in rare diseases, costing several thousand ...

Alexion has routinely featured among lists of top biopharma takeover prospects in the last couple of years, and that was a good call – AstraZeneca has just swooped in with $39 billion cash-and ...